Thanks to an impressive track record of dividend increases, Abbott Labs (NYSE: ABT ) is a staple in dividend investor portfolios; however, sales growth has been hard to come by for the company following the spin-off of AbbVie in 2013.
In a bid to jump start that growth, Abbott is combining a slate of slow-growing generic drugs it sells in developed markets with Mylan's (NASDAQ: MYL ) generic-drug portfolio. While that deal should yield a faster growth rate in the future, investors are right to wonder whether Abbott is overcoming other challenges that are weighing down results today.
In the following slideshow, you'll learn more about Abbott and key considerations to keep in mind when the company reports its second-quarter earnings on July 16.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.